Hydrocortisone Butyrate

ADA HEALTH ANNOUNCES PARTNERSHIP WITH AXA ONEHEALTH Berlin-based global digital health company, Ada Health has announced a partnership with AXA OneHealth, an Egypt-based subsidiary of AXA. Ada was selected as a partner to underpin AXA OneHealth’s digital ecosystem in the region and transform its users’ experience. The partnership will integrate Ada’s AI-based enterprise solutions and provide AXA OneHealth’s users with on-demand access to health guidance. Furthermore, It will help users navigate to the most appropriate care provider within the AXA OneHealth care ecosystem. The partnership also aims to expand Ada’s global presence in improving access, efficiency and outcomes using medical AI. Daniel Nathrath, CEO and co-founder of Ada Health, said: “Through our collaborations, Ada aims to improve access to affordable and effective healthcare at a global scale. This partnership with AXA OneHealth is an important step in our rapid global growth and will positively impact the health of many people in Egypt and beyond. In AXA OneHealth, we have found an innovative and reliable partner who shares our goal of bringing quality healthcare to emerging countries and providing a seamless healthcare journey.” DUBAI EMIRATES ROLLS OUT IATA TRAVEL PASS Dubai-based carrier, Emirates Airline have announced the roll out of the IATA Travel Pass to travellers worldwide. With plans to launch by October, the travel solution aims to simplify travelling during the pandemic, providing more ease for travel across 120 destinations. The travel pass will eliminate the need to carry around printouts of vaccine certificates and COVID-19 tests results to board a flight. “By providing passengers with a one-stop-shop to demystify, manage and process these credentials through a secure automated process, they can arrive at the airport ready-to-fly using automated processes. This will avoid queuing and congestion for document checks – to the benefit of travellers, airlines, airports and governments,” said Nick Careen, IATA senior vice president for operations, safety and security. SPEX CAPITAL & MEDCITY JOINT INVESTMENT CALL London-based life sciences cluster organisation, MedCity and investment firm, Spex Capital announced their first joint call as part of their partnership to identify and fund the next generation of digital health and medtech innovators. Applications are invited from early-stage health-tech ventures with solutions to problems faced by healthcare systems globally. Interested companies will have six weeks to complete their applications for seed or Series A rounds before the call closes at midnight on 27 October 2021. MedCity will use its networks and expertise to attract and assess applications from investment-ready companies developing digital health tech and medtech. Spex Capital will look to invest up to a max of £5 million per target company. The average ticket is expected to between £500k and £2 million. MedCity COO Nicki Bromwich, said: “Together we are tackling one of the biggest challenges for SMEs in this sector – raising finance to support the development and acceleration of the technology into the healthcare system. MedCity will leverage the extensive experience of its team and network of peers to identify and derisk those companies that have potential to make the biggest impact on patient outcomes and the health and social care systems.” SPECTRUMX SHOWS PROMISING RESULTS IN COVID-19 TREATMENT SpectrumX, a UK-based healthcare and pharmaceutical company, announced today its SPC-069 respiratory treatment has shown 100% efficacy in neutralising the most common variants of SARS-CoV-2 (Coronavirus) in an independent in vitro study. Conducted by Medical University Innsbruck, Institute of Hygiene and Medical Microbiology, it investigated the neutralising capacity of SpectrumX’s SPC-069 treatment for the SARS-CoV-2 Wildtype, SARS-CoV-2 Alpha and SARS-CoV-2 Delta strains at various times of exposure. In vitro neutralisation of the virus treated with SPC-069 was 100% in all cases at exposure levels of one minute, five minutes, 10 minutes, 30 minutes and 60 minutes. Damien Hancox, CEO and co-founder of SpectrumX, said: “This study shows the most promising results thus far in our battle against COVID-19 and other respiratory illnesses. Our aim is the delivery of the safest and most effective treatment for all variants of COVID-19, which can dramatically reduce hospitalisation and death amongst patients. This data takes us one step closer to fully deploying the treatment across the UK and Europe and hopefully setting us back on a path to normality.” SYNTHETIC DNA HEALTHTECH SECURES €104M London-based healthtech company, Touchlight has secured €104 million to expand its production of synthetic DNA. The round was led by Bridford Investments Limited and Novator Partners. The production of synthetic DNA has become a concern for scientists since the pandemic. The Pfizer and Moderna coronavirus vaccines use synthetic DNA at the start of the process as a template for mRNA. Touchlight’s synthetic method involves using enzymes to produce genes or gene sequences instead of plasmid. According to chairman of Touchlight, Johnny Ohlson, with this method, there’s less likelihood of antibiotic resistance developing during the development process. “We worked on the development of two vaccines and we’re now more broadly developing relationships with all the mRNA companies,” said Ohlson. “As new variants could come, we need a rapid response for making new vaccines, and our platform helps that.” HCB GROUP ANNOUNCES NEW PARTNERSHIP WITH VIRTUAL GP SERVICE HCB Group has partnered with the patient-focused, GP-led company, Doctor Care Anywhere. The collaboration will provide access to consultations with a GP for individuals not responding effectively to HCB’s Post Covid Syndrome Assessment & Treatment Pathway or for whom a GP consultation is considered necessary following an Initial Case Manager assessment. Dr Bayju Thakar, CEO of Doctor Care Anywhere said: “Digital healthcare is transforming patient lives by making health journeys simpler, faster and more convenient. At Doctor Care Anywhere, we put our patients at the heart of everything we do, delivering high quality care and standards of service. It is very important to us that we partner with organisations who share in that philosophy and we are very pleased to be working with the HCB team to ensure their customers have the ability to access a GP consultation wherever and whenever they need to.” NORTHUMBRIA HEALTHCARE SELECTS CLINISYS WINPATH Northumbria Healthcare NHS FT has chosen the CliniSys laboratory information system (LIMS) as part of a digital strategy to support its drive to improve patient care. The pathology team at Northumbria Healthcare NHS FT has decided to replace their legacy LIMS with WinPath Enterprise, hosted by CliniSys from its UK data centre. Dr Stewart Pattman, consultant chemical pathologist and clinical lead for digital pathology transformation, said: “As a pathology department, we are delighted to have the opportunity to select CliniSys WinPath Enterprise and to design a digital system that supports pathology testing and results for our patients and clinical teams over the next decade and beyond. “As we get into the implementation, we are determined to keep an open mind about the processes that we have at the moment, and to look for opportunities to improve them. “This investment also forms part of a wider digital strategy for the trust, so we will be looking for opportunities to integrate our digital systems with others to create clinical pathways in which diagnostics support safe and effective patient management and decision making.” WOLTERS KLUWER AND ECARESOFT TO DELIVER SOLUTIONS ACROSS MIDDLE EAST Global medical services provider, Wolters Kluwer, Health has announced a collaboration with software company, Ecaresoft to combine the drug screening solution Medi-Span Clinical with Cirrus electronic health record (EHR) and Revenue Cycle Management (RCM) solutions to offer an integrated NPHIES compliant solution to healthcare providers. The move will enable both companies to offer an integrated NPHIES compliant solution to healthcare providers. It will also deliver on a shared global mission to ensure that everyone has access to the best care possible through technology. “Working with Ecaresoft reflects our commitment to measurably improving clinical effectiveness by helping healthcare providers across the region deliver optimal care to their patients,” said Christian Cella, vice president of Medi-Span Clinical, Wolters Kluwer, Health. Alaa Darwish, country manager Middle East, Turkey and Africa, Clinical Effectiveness, Wolters Kluwer, Health added, “With both organisations joining forces to help providers deliver best in class care to patients, we are rising to the challenge of improving care quality and clinical outcomes to populations across the region.” “We are delighted to be working with Wolters Kluwer to provide a cohesive platform that will provide our customers with a greater degree of clinical decision support to enhance patient care and safety,” said Adrian Pina co-CEO, Ecaresoft. CHATBOT TO HELP DOCTORS LEARN MORE ABOUT PATIENTS' HEALTH The Department of Information Technologies of Moscow has launched a Chatbot that will help doctors learn more about patients' health before their appointment. The unified digital healthcare platform operates through artificial intelligence and helps patients convey their health and wellbeing issues to clinicians. This technology will allow physicians to reduce the time to collect information about a patient's health, assess risks, make a more accurate diagnosis, or adjust treatment. Personal history data can be entered into an electronic medical record after filling out a chatbot survey before an appointment with a therapist who is already familiar to the citizens. If the patient or doctor has previously entered this information into the medical record, the chatbot will not collect the anamnesis again. The entered data is stored in the patient's electronic medical record. One can edit them or revert to any of the previous versions using the change history. All information is available in the electronic medical card in the "My Data" section of the mos.ru portal and the "EMIAS.INFO" mobile application. CNWL COLLABORATES WITH DOC ABODE Central and North West London NHS FT (CNWL) has collaborated with healthtech firm Doc Abode to deliver an app-based service so administrative staff can optimise the delivery of the Covid and winter vaccination programme to housebound people. CNWL Community Services found the Doc Abode app met their need, providing an effective digital solution for eligible housebound patients resolving the clinical, operational and administrative burden they faced. The impact of Doc Abode’s technology and success has resulted in zero vaccine wastage, zero clinical safety incidents; greater than 55% increase in staff productivity; 234 days of frontline clinical time saved; and saving in staffing requirements, equal to by eight staff. Lisa Basi, head of Integrated Primary Care at CNWL, said: “The Doc Abode vaccine module has revolutionised the way we deliver our vaccine service. It has vastly reduced our administrative burden but more importantly, it has ensured safety. "It has also doubled the speed and efficiency of the frontline vaccinators, releasing capacity, saving time and reducing vaccine waste. This has meant we have begun vaccinating thousands of vulnerable patients in record time. Since the full rollout of Doc Abode’s vaccination module in April 2021, Camden has been one of the highest performing of all 32 boroughs in London.”